The Silverstein Foundation

Founded in 2017, The Silverstein Foundation for Parkinson's with GBA is dedicated to advancing research and developing new therapies for Parkinson's disease, particularly focusing on individuals with glucocerebrosidase (GBA) mutations. The organization aims to raise awareness about Parkinson’s disease associated with GBA mutations, promote relevant clinical trials, and aggressively pursue innovative therapeutic approaches. Their market focus includes patients, researchers, and healthcare professionals involved in Parkinson's disease treatment and research.

Notable affiliates of The Silverstein Foundation include leading scientists and researchers in the field of neurodegenerative diseases. The foundation has garnered support from prominent investors and institutions dedicated to medical research. Key achievements include sponsoring significant events like the GBA1 Meeting and funding early-stage programs with potential therapeutic breakthroughs. The overall impact of the foundation lies in its contribution to accelerating the development of effective treatments for Parkinson's disease, thereby improving the quality of life for affected individuals.